Recruiting

Observational Study

Sponsor:

Case Comprehensive Cancer Center

Code:

NCT06687603

Conditions

Barrett Esophagus

Gastroesophageal Reflux

Esophageal Adenocarcinoma

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Accepted

Interventions

EsoCheck

EsoGuard

Study Details

Brief summary:

The goal of this clinical trial is to develop a method to detect Barrett's esophagus in individuals with a new office based diagnostic test. Barrett's esophagus is a condition in which the flat pink lining of the swallowing tube that connects the mouth to the stomach (the esophagus) becomes damaged by acid reflux. The main question it aims to answer is: Can this approach demonstrate efficacy for screening of Barrett's esophagus?

Participants will:

  • Participate in a questionnaire.
  • Undergo a capsule balloon test, called EsoCheck.
  • Have their EsoCheck sample sent to the laboratory for an EsoGuard test, which is used to detect Barrett's esophagus.
  • Participants will undergo upper endoscopy as part of standard of care.

Conditions

Barrett Esophagus

Gastroesophageal Reflux

Esophageal Adenocarcinoma

Study ID

NCT06687603

Start date

Mar 10, 2025

Status verified date

Sep, 2026

Completion date

Sep 27, 2029

Anticipated

Primary completion date

Sep 27, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Accepted

Inclusion Criteria:

Patients undergoing screening colonoscopy are an accessible cohort for BE screening and are also a reasonable representation of the general population. Permission will be obtained from colonoscopy physicians for researchers to contact and recruit patients for this study. Patients without GERD, who are at risk for BE, and who have not had a prior EGD, will be recruited prior to or at the time of scheduled colonoscopy.(9) Those eligible will be:

  • Adults who have not had prior EGD within past ten years, and are able to provide informed consent, and who have:
  • No known coagulopathy, no known esophageal varices, not on chronic anticoagulation therapy, and have:
  • No significant dysphagia or odynophagia; but who do have:
  • Absence of GERD (absence of weekly heartburn or regurgitation, not on medications for GERD), and are:
  • Adults > age 50, who also have two or more added risk factors for BE from the set of: central obesity (waist size > 35 inches for women and > 40 inches for men), current smoker or smoking history > 10 pack years, white race, male sex, confirmed history of BE/EAC in at least two family members, with one a first degree relative. While BE is most highly prevalent in white males, a black female over age 50 with obesity and a positive smoking history would also be at increased BE risk and would equally meet eligibility criteria.
  • Subjects must have the ability to understand and the willingness to sign a written informed consent document.
  • Subjects must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

  • History of prior EGD procedure in past ten years
  • Inability to provide written informed consent
  • History of weekly of more frequent heartburn or regurgitation for five or more years
  • On anti-coagulant drug(s) that cannot be temporarily discontinued or coagulopathy with INR > 1.5
  • Known history of esophageal varices or esophageal stricture
  • Any contraindication, as deemed in Investigator's medical judgment, to undergoing the EsoCheck procedure, undergoing the EGD procedure, and/or having biopsies taken, including but not limited to due to comorbidities such as coagulopathy or a known history of esophageal diverticula, esophageal fistula and/or esophageal ulceration
  • History of difficulty swallowing (dysphagia) or painful swallowing (odynophagia), including swallowing pills
  • Oropharyngeal tumor
  • History of esophageal or gastric surgery, with exception of uncomplicated surgical fundoplication procedure

Study Design

Enrollment

800 participants

Anticipated

Intervention Model

Single group

Primary purpose

Prevention

Interventions and Outcome Measures

Arms

experimental: EsoCheck + EsoGuard

Participants will undergo an EsoCheck test. The sample produced by the EsoCheck will be sent to LucidDx where the EsoGuard assay will be performed.

Interventions

EsoCheck

FDA-approved, non-endoscopic, encapsulated swallowable balloon. EsoCheck will produce a sample which will subsequently be tested with EsoGuard assay. The EsoCheck is performed and completed in approximately 5 minutes.

EsoGuard

Approved laboratory, methylated DNA panel that detects esophageal neoplasia. The EsoGuard assay tests the EsoCheck samples to detect BE in GERD participants.

Primary outcome measure

  • Positive predictive value for Barret's Esophagus in EsoCheck/EsoGuard positive participants [ Time Frame: Up to 5 years ]
  • Barrett's Esophagus prevalence in EsoCheck/EsoGuard test negative subjects from a high-risk GERD negative population [ Time Frame: Up to 5 years ]
  • Tissue origins of true positive versus false positive EsoCheck/EsoGuard tests in non-GERD screening population [ Time Frame: Up to 5 years ]

Central Contacts and Locations

Central contacts

Locations

University of Colorado

Recruiting

Aurora, Colorado, United States, 80045

Principal Investigator:

Sachin Wani, MD

Johns Hopkins Hospital

Recruiting

Baltimore, Maryland, United States, 21287

Principal Investigator:

Marcia Canto, MD

University of North Carolina at Chapel Hill

Recruiting

Chapel Hill, North Carolina, United States, 027599

Principal Investigator:

Nicholas Shaheen, MD

University Hospitals Cleveland Medical Center

Recruiting

Cleveland, Ohio, United States, 44016

Principal Investigator:

Amitabh Chak, MD

Cleveland Clinic Taussig Cancer Center

Recruiting

Cleveland, Ohio, United States, 44195

Principal Investigator:

Prashanti Thota, MD

More Information

Sponsor

Case Comprehensive Cancer Center

Last update posted

Sep 15, 2026

Last verified

Sep, 2026

Keywords

  • Esophagus
  • Non-endoscopic

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-26. This information was provided to ClinicalTrials.gov by Case Comprehensive Cancer Center on 2026-09-15. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.